Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

医学 安慰剂 2型糖尿病 中止 体质指数 人口 内科学 减肥 超重 肥胖 养生 糖尿病 意向治疗分析 随机对照试验 临床终点 物理疗法 内分泌学 病理 替代医学 环境卫生
作者
William Timothy Garvey,Juan P Frias,Ania M. Jastreboff,Carel Wynand le Roux,Naveed A. Sattar,Diego Aizenberg,Huzhang Mao,Shuyu Zhang,Nadia N. Ahmad,Mathijs C. M. Bunck,Imane Benabbad,X. Zhang,Franklin Ábalos,Federico Pérez Manghi,Cesar Javier Zaidman,Marisa L. Vico,Diego Aizenberg,Pablo R. Costanzo,L. Serra,Ignacio J. Mackinnon
出处
期刊:The Lancet [Elsevier BV]
卷期号:402 (10402): 613-626 被引量:999
标识
DOI:10.1016/s0140-6736(23)01200-x
摘要

Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, versus placebo, for weight management in people living with obesity and type 2 diabetes.This phase 3, double-blind, randomised, placebo-controlled trial was conducted in seven countries. Adults (aged ≥18 years) with a body-mass index (BMI) of 27 kg/m2 or higher and glycated haemoglobin (HbA1c) of 7-10% (53-86 mmol/mol) were randomly assigned (1:1:1), using a computer-generated random sequence via a validated interactive web-response system, to receive either once-weekly, subcutaneous tirzepatide (10 mg or 15 mg) or placebo for 72 weeks. All participants, investigators, and the sponsor were masked to treatment assignment. Coprimary endpoints were the percent change in bodyweight from baseline and bodyweight reduction of 5% or higher. The treatment-regimen estimand assessed effects regardless of treatment discontinuation or initiation of antihyperglycaemic rescue therapy. Efficacy and safety endpoints were analysed with data from all randomly assigned participants (intention-to-treat population). This trial is registered with ClinicalTrials.gov, NCT04657003.Between March 29, 2021, and April 10, 2023, of 1514 adults assessed for eligibility, 938 (mean age 54·2 years [SD 10·6], 476 [51%] were female, 710 [76%] were White, and 561 [60%] were Hispanic or Latino) were randomly assigned and received at least one dose of tirzepatide 10 mg (n=312), tirzepatide 15 mg (n=311), or placebo (n=315). Baseline mean bodyweight was 100·7 kg (SD 21·1), BMI 36·1 kg/m2 (SD 6·6), and HbA1c 8·02% (SD 0·89; 64·1 mmol/mol [SD 9·7]). Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12·8% (SE 0·6) and -14·7% (0·5), respectively, and -3·2% (0·5) with placebo, resulting in estimated treatment differences versus placebo of -9·6% percentage points (95% CI -11·1 to -8·1) with tirzepatide 10 mg and -11·6% percentage points (-13·0 to -10·1) with tirzepatide 15 mg (all p<0·0001). More participants treated with tirzepatide versus placebo met bodyweight reduction thresholds of 5% or higher (79-83% vs 32%). The most frequent adverse events with tirzepatide were gastrointestinal-related, including nausea, diarrhoea, and vomiting and were mostly mild to moderate in severity, with few events leading to treatment discontinuation (<5%). Serious adverse events were reported by 68 (7%) participants overall and two deaths occurred in the tirzepatide 10 mg group, but deaths were not considered to be related to the study treatment by the investigator.In this 72-week trial in adults living with obesity and type 2 diabetes, once-weekly tirzepatide 10 mg and 15 mg provided substantial and clinically meaningful reduction in bodyweight, with a safety profile that was similar to other incretin-based therapies for weight management.Eli Lilly and Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
8如有法规完成签到,获得积分10
刚刚
任性的如南完成签到,获得积分10
刚刚
niko发布了新的文献求助10
1秒前
爪子完成签到,获得积分10
1秒前
1秒前
念l完成签到,获得积分10
1秒前
1秒前
kke完成签到,获得积分10
1秒前
Winky发布了新的文献求助10
1秒前
2秒前
微眠完成签到,获得积分10
2秒前
隐形曼青的应助被梦梦梦采纳,获得10
2秒前
gentleripper发布了新的文献求助10
2秒前
littlejin完成签到 ,获得积分10
2秒前
巴拉巴拉巴拉拉完成签到,获得积分10
2秒前
LL发布了新的文献求助10
3秒前
3秒前
JAY完成签到,获得积分10
3秒前
3秒前
桐桐的应助被lucy采纳,获得10
3秒前
lxy完成签到,获得积分10
3秒前
H韩完成签到,获得积分10
3秒前
可爱的函函的应助被刘斌采纳,获得30
4秒前
77发布了新的文献求助10
4秒前
4秒前
花木森林jl091121完成签到,获得积分10
4秒前
4秒前
ze完成签到,获得积分10
4秒前
无限的尔安完成签到,获得积分10
4秒前
4秒前
SCI的芷蝶发布了新的文献求助10
4秒前
田田田田完成签到,获得积分10
4秒前
念l发布了新的文献求助10
5秒前
任斯发布了新的文献求助10
5秒前
星海湾追风完成签到,获得积分10
5秒前
Army616完成签到,获得积分10
5秒前
Almas完成签到 ,获得积分10
5秒前
asss发布了新的文献求助10
5秒前
张张完成签到,获得积分10
6秒前
充电宝的应助被Scout采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8167280
求助须知:如何正确求助?哪些是违规求助? 9560076
关于积分的说明 21754886
捐赠科研通 7758257
什么是DOI,文献DOI怎么找? 3429309
关于科研通互助平台的介绍 2553653
邀请新用户注册赠送积分活动 2474136